Share on StockTwits

Medivation (NASDAQ:MDVN) CFO Clarence Patrick Machado sold 40,000 shares of Medivation stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $73.46, for a total value of $2,938,400.00. Following the transaction, the chief financial officer now directly owns 30,830 shares of the company’s stock, valued at approximately $2,264,772. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Chardan Capital reiterated a “buy” rating on shares of Medivation in a research note to investors on Monday. They now have a $100.00 price target on the stock. Separately, analysts at Citigroup Inc. raised their price target on shares of Medivation to $124.00 in a research note to investors on Monday. Finally, analysts at Sanford C. Bernstein downgraded shares of Medivation from an “outperform” rating to a “market perform” rating in a research note to investors on Monday. They now have a $92.00 price target on the stock, up previously from $84.00. One analyst has rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $90.18.

Medivation (NASDAQ:MDVN) traded up 1.68% during mid-day trading on Thursday, hitting $74.65. The stock had a trading volume of 1,010,585 shares. Medivation has a 52-week low of $41.89 and a 52-week high of $87.46. The stock’s 50-day moving average is $71.21 and its 200-day moving average is $61.75. The company’s market cap is $5.633 billion.

Medivation (NASDAQ:MDVN) last issued its quarterly earnings data on Thursday, January 30th. The company reported ($0.43) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.14) by $0.29. On average, analysts predict that Medivation will post $-0.69 earnings per share for the current fiscal year.

Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.